東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Meta-analysis methods in the cost-ef...

University of Southern California., Pharmaceutical Economics and Policy.

FindBook

Google Book

Amazon

博客來

Meta-analysis methods in the cost-effectiveness analysis of mammography screening.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Meta-analysis methods in the cost-effectiveness analysis of mammography screening./
作者:	Zammit, Danielle Christine.
面頁冊數:	223 p.
附註:	Adviser: Joel W. Hay.
Contained By:	Dissertation Abstracts International68-05B.
標題:	Economics, General. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3266756
ISBN:	9780549052456

Meta-analysis methods in the cost-effectiveness analysis of mammography screening.
Zammit, Danielle Christine.

Meta-analysis methods in the cost-effectiveness analysis of mammography screening. - 223 p.

Adviser: Joel W. Hay.

Thesis (Ph.D.)--University of Southern California, 2007.

The objectives of this research were: to conduct quality-weighted random effects meta-analysis of the effect of mammography (MM) screening on breast cancer (BC) mortality, to create a framework to analyze the cost-effectiveness of MM screening, designed specifically to isolate the effect of MM on life expectancy (LE) with BC, and to run full sensitivity analyses of this model.

ISBN: 9780549052456Subjects--Topical Terms:

1017424
Economics, General.

Meta-analysis methods in the cost-effectiveness analysis of mammography screening.
LDR:03240nam 2200325 a 45 001 861652
005 20100720
008 100720s2007 ||||||||||||||||| ||eng d
020 $a 9780549052456
035 $a (UMI)AAI3266756
035 $a AAI3266756
040 $a UMI $c UMI
100 1 $a Zammit, Danielle Christine. $3 1029371
245 1 0 $a Meta-analysis methods in the cost-effectiveness analysis of mammography screening.
300 $a 223 p.
500 $a Adviser: Joel W. Hay.
500 $a Source: Dissertation Abstracts International, Volume: 68-05, Section: B, page: 2989.
502 $a Thesis (Ph.D.)--University of Southern California, 2007.
520 $a The objectives of this research were: to conduct quality-weighted random effects meta-analysis of the effect of mammography (MM) screening on breast cancer (BC) mortality, to create a framework to analyze the cost-effectiveness of MM screening, designed specifically to isolate the effect of MM on life expectancy (LE) with BC, and to run full sensitivity analyses of this model.
520 $a Methods. The relative risk (RR) of BC mortality in screened vs. control groups was estimated by incorporating a study-specific quality weight into inversevariance weighted random effects (RE) analysis. Cost-effectiveness of MM screening vs. no screening was analyzed on a base case of a white female population being screened annually from the age of 40, on a lifetime horizon from the societal perspective. The RR of BC mortality was used to estimate life expectancy with BC in screened women. Direct and indirect costs included MM, its workup and BC management. Extensive sensitivity analyses were conducted.
520 $a Results. Significant 20% and 22% reductions in BC mortality were observed in screened women of any age and above age fifty [RR: 0.78(95%CI=0.70--0.88)] respectively. CIs were narrower than those from RE analysis. Under fifty, the result reduced to a fixed effects analysis: 0.84(95%CI=0.73--0.97). No trend of effect with study quality was observed, although under fifty, seven studies were pooled before a significant effect was observed. MM is most cost-effective at age 60, (ICER: $3 8,876/QALY), being slightly less so at 40 (ICER: $4 7,991/QALY). The ICER (incremental cost-effectiveness ratio) increases steadily after age 65, reaching its highest estimation at age 80. The model was very sensitive to the RR of BC mortality with MM. SA also showed sensitivity to discount rate, but relative robustness to other parameters.
520 $a Conclusions. Quality scores may be used in a meta-analysis to account for between-study variance due to heterogeneity. Evidence of MM benefit under 50 may depend on the number and quality of studies included. The most cost-effective program tested was to start annual MM at age 40, switching to 2-year intervals at 50, and stopping at age 70. This framework can be used for the cost-effectiveness analysis of screening recommendations, and future policy analyses.
590 $a School code: 0208.
650 4 $a Economics, General. $3 1017424
650 4 $a Health Sciences, Health Care Management. $3 1017922
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0501
690 $a 0572
690 $a 0769
710 2 $a University of Southern California. $b Pharmaceutical Economics and Policy. $3 1029370
773 0 $t Dissertation Abstracts International $g 68-05B.
790 $a 0208
790 1 0 $a Hay, Joel W., $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3266756